AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$LQDA

Bloch Stephen M sold $5.5M of LQDA (indirect holdings)

Bloch Stephen M sold 84,800 indirectly-held shares of Liquidia Corp (LQDA) at an average of $64.95 ($64.14–$66.08, $5.51M total) across 4 trades over 2026-06-04 to 2026-06-05.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jun 8, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or correlate with any concurrent fundamental news, but this filing alone doesn’t change the company’s outlook.

02

Market read

Primary-source insider selling disclosure; potential minor sentiment impact rather than a fundamental repricing catalyst.

03

What to watch

The filing shows indirect ownership and post-sale holdings (1.785M shares), but provides no stated reason for the sale or any concurrent operational/clinical update.

Relevance 6/10Novelty 8/10Timing: Filed June 8; trades executed June 4–5.

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia Corp director Stephen M. Bloch sold $5.51M of LQDA shares via open-market transactions (Form 4) dated June 4–5.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than a re-rating catalyst.

Evidence & confidence

The filing is primary-source and time-stamped, but it discloses only an insider sale amount/price range without new company fundamentals or guidance.

Market effects

Sector

No direct sector read-through; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be routine liquidity/portfolio rebalancing; the absence of a 10b5-1 plan doesn’t automatically imply negative fundamentals.

Key entities

  • issuer
    Liquidia Corp

    Company whose director insider sale is disclosed on SEC Form 4.

  • insider
    Stephen M. Bloch

    Director who sold LQDA shares in open-market transactions.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

zacks.com
$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

investing.com
$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

finance.yahoo.com
$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.

finance.yahoo.com